Ex vivo decrease in uranium diffusion through intact and excoriated pig ear skin by a calixarene nanoemulsion - Archive ouverte HAL
Article Dans Une Revue European Journal of Pharmaceutics and Biopharmaceutics Année : 2011

Ex vivo decrease in uranium diffusion through intact and excoriated pig ear skin by a calixarene nanoemulsion

Résumé

Cutaneous contamination by radionuclides is a major concern in the nuclear industry. In case of skin exposure to uranium, no efficient emergency treatment is available to remove the actinide from the skin. For this purpose, we developed a nanoemulsion containing calixarene molecules displaying good chelating properties towards uranium. In this paper, we describe the ability of this formulation to trap uranium and limit its transfer from the cutaneous contaminated site into the blood. Uranium percutaneous diffusion kinetics was assessed with Franz cells over 24 h through intact and excoriated pig ear skin biopsies, after or without application of the nanoemulsion. Uranium distribution in the skin layers was analysed by SIMS microscopy. The results showed that prompt application of the calixarene nanoemulsion allows a 94% and 98% reduction of the amount of uranium diffused respectively through intact and excoriated skin. The formulation is still efficient in case of delayed application up to 30 minutes since the 24 h-uranium transfer through excoriated skin is reduced by 71%. Besides, no accumulation of uranium or uranium- calixarene chelate was observed in the different skin layers. In conclusion, this study demonstrated the efficiency of the calixarene nanoemulsion, which can be regarded as a promising treatment for uranium cutaneous contamination. © 2011 Elsevier B.V.
Fichier non déposé

Dates et versions

hal-02962933 , version 1 (09-10-2020)

Identifiants

Citer

A. Spagnul, C. Bouvier-Capely, G. Phan, G. Landon, C. Tessier, et al.. Ex vivo decrease in uranium diffusion through intact and excoriated pig ear skin by a calixarene nanoemulsion. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79 (2), pp.258--267. ⟨10.1016/j.ejpb.2011.05.004⟩. ⟨hal-02962933⟩

Collections

IRSN
14 Consultations
0 Téléchargements

Altmetric

Partager

More